Compare Glenmark Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PANACEA BIOTECH - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PANACEA BIOTECH GLENMARK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 11.9 12.2 97.5% View Chart
P/BV x 1.7 2.9 58.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 GLENMARK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
PANACEA BIOTECH
Mar-18
GLENMARK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs712364 195.5%   
Low Rs484129 374.6%   
Sales per share (Unadj.) Rs349.696.8 361.3%  
Earnings per share (Unadj.) Rs32.8-12.4 -264.2%  
Cash flow per share (Unadj.) Rs44.3-2.9 -1,554.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.650.4 394.2%  
Shares outstanding (eoy) m282.1761.25 460.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.5 67.1%   
Avg P/E ratio x18.2-19.9 -91.7%  
P/CF ratio (eoy) x13.5-86.4 -15.6%  
Price / Book Value ratio x3.04.9 61.5%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62515,101 1,116.6%   
No. of employees `00012.02.5 487.7%   
Total wages/salary Rs m20,5611,516 1,356.3%   
Avg. sales/employee Rs Th8,196.02,401.9 341.2%   
Avg. wages/employee Rs Th1,708.1614.2 278.1%   
Avg. net profit/employee Rs Th768.5-307.9 -249.5%   
INCOME DATA
Net Sales Rs m98,6555,928 1,664.2%  
Other income Rs m2,08182 2,529.0%   
Total revenues Rs m100,7366,010 1,676.1%   
Gross profit Rs m15,858845 1,876.0%  
Depreciation Rs m3,259585 556.8%   
Interest Rs m3,3461,006 332.7%   
Profit before tax Rs m11,335-664 -1,708.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m02 0.0%   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,75699 3,809.7%   
Profit after tax Rs m9,250-760 -1,217.1%  
Gross profit margin %16.114.3 112.7%  
Effective tax rate %33.1-14.9 -223.0%   
Net profit margin %9.4-12.8 -73.1%  
BALANCE SHEET DATA
Current assets Rs m66,9685,603 1,195.1%   
Current liabilities Rs m40,2116,910 581.9%   
Net working cap to sales %27.1-22.0 -123.0%  
Current ratio x1.70.8 205.4%  
Inventory Days Days83206 40.5%  
Debtors Days Days8184 97.0%  
Net fixed assets Rs m33,3229,941 335.2%   
Share capital Rs m28261 460.4%   
"Free" reserves Rs m55,7703,026 1,843.3%   
Net worth Rs m56,0523,087 1,815.8%   
Long term debt Rs m35,7385,707 626.2%   
Total assets Rs m132,88816,076 826.6%  
Interest coverage x4.40.3 1,289.2%   
Debt to equity ratio x0.61.8 34.5%  
Sales to assets ratio x0.70.4 201.3%   
Return on assets %9.51.5 619.9%  
Return on equity %16.5-24.6 -67.0%  
Return on capital %17.83.9 454.9%  
Exports to sales %024.0 0.0%   
Imports to sales %017.5 0.0%   
Exports (fob) Rs mNA1,424 0.0%   
Imports (cif) Rs mNA1,040 0.0%   
Fx inflow Rs m62,9981,600 3,937.3%   
Fx outflow Rs m22,8591,131 2,020.3%   
Net fx Rs m40,140469 8,566.1%   
CASH FLOW
From Operations Rs m13,2421,180 1,122.0%  
From Investments Rs m-6,990553 -1,264.2%  
From Financial Activity Rs m-7,387-1,644 449.5%  
Net Cashflow Rs m-2,97190 -3,311.9%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.6 1,150.0%  
FIIs % 34.4 1.3 2,646.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.6 44.5%  
Shareholders   56,727 10,259 552.9%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS